1. Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection
- Author
-
José Carlos Mancera Gracia, Ivan Trus, Florian Krammer, Eric Cox, Lieve Sys, Gerwin Claes, Yu Qiu, Kristien Van Reeth, and Han Versnaeyen
- Subjects
0301 basic medicine ,H5N1 vaccine ,Influenza vaccine ,viruses ,030106 microbiology ,Immunology ,HEMAGGLUTININ STALK ANTIBODIES ,US SWINE ,A VIRUSES ,H5N1 genetic structure ,Article ,Virus ,Microbiology ,BINDING SITE DETERMINE ,03 medical and health sciences ,NORTH-AMERICAN ,MEMORY B-CELLS ,INFECTION ,Live attenuated influenza vaccine ,PIGS ,Pharmacology (medical) ,Veterinary Sciences ,H5N1 VACCINE ,RC254-282 ,Pharmacology ,biology ,Biology and Life Sciences ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,virus diseases ,RC581-607 ,Vaccine efficacy ,Virology ,Vaccination ,030104 developmental biology ,Infectious Diseases ,biology.protein ,Immunologic diseases. Allergy ,Neuraminidase ,ANTIGENICALLY DISTINCT - Abstract
The emergence of multiple novel lineages of H1 and H3 influenza A viruses in swine has confounded control by inactivated vaccines. Because of substantial genetic and geographic heterogeneity among circulating swine influenza viruses, one vaccine strain per subtype cannot be efficacious against all of the current lineages. We have performed vaccination-challenge studies in pigs to examine whether priming and booster vaccinations with antigenically distinct H3N2 swine influenza viruses could broaden antibody responses and protection. We prepared monovalent whole inactivated, adjuvanted vaccines based on a European and a North American H3N2 swine influenza virus, which showed 81.5% aa homology in the HA1 region of the hemagglutinin and 83.4% in the neuraminidase. Our data show that (i) Priming with European and boosting with North American H3N2 swine influenza virus induces antibodies and protection against both vaccine strains, unlike prime-boost vaccination with a single virus or a single administration of bivalent vaccine. (ii) The heterologous prime-boost vaccination enhances hemagglutination inhibiting, virus neutralizing and neuraminidase inhibiting antibody responses against H3N2 viruses that are antigenically distinct from both vaccine strains. Antibody titers to the most divergent viruses were higher than after two administrations of bivalent vaccine. (iii) However, it does not induce antibodies to the conserved hemagglutinin stalk or to other hemagglutinin subtypes. We conclude that heterologous prime-boost vaccination might broaden protection to H3N2 swine influenza viruses and reduce the total amount of vaccine needed. This strategy holds potential for vaccination against influenza viruses from both humans and swine and for a better control of (reverse) zoonotic transmission of influenza viruses., Influenza: More efficient, more protective vaccinations Boosting an influenza vaccine with a different strain offers twice the protection for half the volume of vaccine. Pigs and humans need two doses of killed influenza vaccine—a “priming” dose, with a “booster” given approximately 4 weeks after—in order to provide immunity. Kristien Van Reeth, of Belgium’s Ghent University, and collaborators demonstrated that differing the strain of the primer and booster elicits antibodies that protect against both strains, negating the need for two doses of both strains. The swine vaccinated in Van Reeth’s study also had increased immunity against strains that the animals were not vaccinated against but bore similarities to the viruses used. This cross-protection corresponds with conclusions from similar research into other animals and could eliminate the need for unnecessary vaccinations whilst increasing vaccine efficacy in swine and presumably in humans.
- Published
- 2017